Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study (PROmyBETAapp)

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Device: myBETAapp; Drug: Interferon beta-1b (Betaferon, BAY86-5046); Device: Betaconnect auto-injector

Study type: Observational

Funder types: Industry

Identifiers

NCT03134573

18462

BF1504 (Other Identifier)

Details and patient eligibility

About

The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness tracker in the myBETAapp will be observed for 3 months.

Enrollment: 96 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged ≥ 18 years.
• Patients on treatment with Betaferon (every Betaferon box contains a "Mixject" number, which is a product specific number unrelated to the study. Only patients prescribed Betaferon for their MS will be able to use the myBETAapp and participate in the study).
• Patients must be using the myBETAapp.
• Electronic informed consent must be obtained.

Exclusion criteria

-There are no exclusion criteria for participation in this study.

Trial design

96 participants in 1 patient group

Multiple Sclerosis

Description:

Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp

Treatment:

Drug: Interferon beta-1b (Betaferon, BAY86-5046)

Device: Betaconnect auto-injector

Device: myBETAapp